Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kajsa P Kanebratt

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 24, 2007
HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humansKajsa P Kanebratt, Tommy B Andersson
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 2008
Evaluation of HepaRG cells as an in vitro model for human drug metabolism studiesKajsa P Kanebratt, Tommy B Andersson
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 4, 2012
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluationErik Sjögren, Petter Svanberg, Kajsa P Kanebratt
Expert Opinion on Drug Metabolism & Toxicology|May 10, 2012
The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in humanTommy B Andersson, Kajsa P Kanebratt, John Gerry Kenna
Plos One|September 12, 2024
3D cell aggregates amplify diffusion signalsHamidreza Arjmandi, Kajsa P Kanebratt, Liisa Vilén, et al.
British Journal of Pharmacology|March 26, 2018
Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450sBo Lindmark, Anna Lundahl, Kajsa P Kanebratt, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 3, 2018
Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug InteractionsLuna Prieto Garcia, David Janzén, Kajsa P Kanebratt, et al.
British Journal of Clinical Pharmacology|November 14, 2008
4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicinUlf Diczfalusy, Kajsa P Kanebratt, Eva Bredberg, et al.
British Journal of Clinical Pharmacology|November 3, 2012
A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 inductionYvonne Mårde Arrhén, Hanna Nylén, Anita Lövgren-Sandblom, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 2016
Managing the Risk of CYP3A Induction in Drug Development: A Strategic ApproachBarry C Jones, Helen Rollison, Susanne Johansson, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 24, 2007
HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humansKajsa P Kanebratt, Tommy B Andersson
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 2008
Evaluation of HepaRG cells as an in vitro model for human drug metabolism studiesKajsa P Kanebratt, Tommy B Andersson
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 4, 2012
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluationErik Sjögren, Petter Svanberg, Kajsa P Kanebratt
Expert Opinion on Drug Metabolism & Toxicology|May 10, 2012
The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in humanTommy B Andersson, Kajsa P Kanebratt, John Gerry Kenna
Plos One|September 12, 2024
3D cell aggregates amplify diffusion signalsHamidreza Arjmandi, Kajsa P Kanebratt, Liisa Vilén, et al.
British Journal of Pharmacology|March 26, 2018
Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450sBo Lindmark, Anna Lundahl, Kajsa P Kanebratt, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 3, 2018
Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug InteractionsLuna Prieto Garcia, David Janzén, Kajsa P Kanebratt, et al.
British Journal of Clinical Pharmacology|November 14, 2008
4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicinUlf Diczfalusy, Kajsa P Kanebratt, Eva Bredberg, et al.
British Journal of Clinical Pharmacology|November 3, 2012
A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 inductionYvonne Mårde Arrhén, Hanna Nylén, Anita Lövgren-Sandblom, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 2016
Managing the Risk of CYP3A Induction in Drug Development: A Strategic ApproachBarry C Jones, Helen Rollison, Susanne Johansson, et al.
Pageof 2